Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Compugen Ltd (NQ: CGEN )

0.7008 +0.0438 (+6.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 734,531
Open 0.7000
Bid (Size) 0.6700 (1)
Ask (Size) 0.7300 (18)
Prev. Close 0.6570
Today's Range 0.6700 - 0.7073
52wk Range 0.6570 - 7.480
Shares Outstanding 86,433,432
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
5 Top Stocks Cathie Wood Sold This Week
August was not a pleasant month for Cathie Wood and ARKK as the ETF experienced outflows of $803 million, the most since last September. 
Via InvestorPlace
Analyst Ratings for Compugen
Within the last quarter, Compugen (NASDAQ:CGEN) has observed the following analyst ratings: 
Via Benzinga

Performance

YTD
-84.90%
-84.90%
1 Month
-33.26%
-33.26%
3 Month
-66.79%
-66.79%
6 Month
-78.95%
-78.95%
1 Year
-88.42%
-88.42%

More News

Read More
Truist Securities Maintains Buy Rating for Compugen: Here's What You Need To Know
Via Benzinga
Cathie Wood Scoops Up Over $20M Worth Of Fate Therapeutics Shares, Dumps More Twitter Stock
Via Benzinga
JMP Securities Maintains Market Outperform Rating for Compugen: Here's What You Need To Know
Via Benzinga
Compugen: Q2 Earnings Insights
Via Benzinga
Recap: Compugen Q1 Earnings
Via Benzinga
Earnings Scheduled For May 16, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
This Analyst Lowers Price Target On Lyft; Also Check Out Some Other Major PT Changes
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Earnings Preview For Compugen
Via Benzinga
Earnings Outlook For Compugen
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Via Benzinga
This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday
Via Benzinga
World Markets News For Friday
Via Talk Markets
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Gold up, Stocks down
Via Talk Markets
Inflation inflating
Via Talk Markets
A News Blizzard
Via Talk Markets
The Last Day In January
Via Talk Markets
Drug Troubles
Via Talk Markets
World Markets News
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.